Early Betaferon Treatment Can Delay MS Progression

There is new data that recently came out that confirms early treatment of Betaferon, or interferon beta-1b, in patients showing initial signs of multiple sclerosis can help delay the onset of multiple sclerosis. Early treatment using Betaferon can delay the onset of clinically definite multiple sclerosis (CDMS) by 35 percent and about 45 percent for McDonald MS for a period of five years.

The results came from findings of BENEFIT, or Betaferon in Newly Emerging multiple sclerosis For Initial Treatment. The study covered a period of five years which involved administering Betaferon treatment to patients exhibiting the earliest signs of MS.

According to Dr. Mark Freedman, Professor of Neurology at the University of Ottawa and head of the study, "The BENEFIT five-year results are the first and only prospective data to confirm a continuous benefit over five years when treatment is initiated shortly after the earliest sign of MS. These results confirm that treatment with Betaferon after the first MS event or attack can reduce the risk of developing MS over five years compared to delayed treatment."

The key findings of the BENEFIT five year study showed that administering interferon beta-1b at the first clinical sign of MS helped to delay the development of CDMS by more than two years. Patients who were also treated early with interferon beta-1b had a greater reduction in relapse rate as compared with those who went through delayed treatment.

The early treatment also helped significantly reduce the development of newly active brain lesions as compared to patients who underwent delayed treatment. In the BENEFIT study, those patients treated early with Betaferon exhibited a high level of acceptance for the said drug. About two thirds of the group continued with the treatment for five years.

Source: medicalnewstoday.com/articles/125641.php

 

 
You can leave a response, or trackback from your own site.